Literature DB >> 8573556

Digoxin and increased mortality among patients recovering from acute myocardial infarction: importance of digoxin dose. The SPRINT Study Group.

J Leor1, U Goldbourt, B Rabinowitz, H Reicher-Reiss, V Boyko, E Kaplinsky, S Behar.   

Abstract

Digoxin therapy has been suggested to increase mortality risk in survivors of acute myocardial infarction. Since digoxin is a drug with a narrow therapeutic/toxic ratio, we raised the hypothesis that the association between digoxin and post myocardial infarction mortality may have a dose-dependent relationship. The purpose of this study was to evaluate this hypothesis. We retrospectively analyzed data from 1731 survivors of acute myocardial infarction. At the time of hospital discharge, 175 patients (10%) were taking digoxin. The exact dosage of digoxin was ascertained in 153 (87%) patients. Patients were divided into two groups based on the weekly dosage of digoxin at hospital discharge: The first group included 41 patients who were treated with a low dose (< or = 1.5 mg per week, usually 0.125 mg daily). The second group included 112 patients treated with a full dose (> 1.5 mg per week, usually 0.25 mg daily). Both groups were comparable with regard to mean age, gender, history of prior myocardial infarction, diabetes mellitus, hypertension, and prior angina. There were no significant differences in the incidence of in-hospital complications, such as heart failure, atrial fibrillation, ventricular tachycardia, ventricular fibrillation, and postinfarction angina. One year mortality was significantly higher among patients treated with a full dose [19 of 112 (17%)] than patients treated with a low dose of digoxin [1 of 41 (2%); p < 0.02] Multivariate analysis performed by the Cox proportional hazards model identified treatment with a full dose of digoxin as an independent determinant associated with increased death during the first year after myocardial infarction (hazard ratio 10.7; 95% confidence interval 1.4-80.5). Thus, mortality among myocardial infarction survivors treated with digoxin was related to a full-dose therapy. Patients treated with a low dose experienced a low mortality rate. Our findings raise concern that digoxin may exert a dose-dependent deleterious effect upon the survival of patients recovering from acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8573556     DOI: 10.1007/bf00878556

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  22 in total

Review 1.  Digoxin. A neurohormonal modulator in heart failure?

Authors:  M Gheorghiade; D Ferguson
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

2.  Factors influencing infarct size following experimental coronary artery occlusions.

Authors:  P R Maroko; J K Kjekshus; B E Sobel; T Watanabe; J W Covell; J Ross; E Braunwald
Journal:  Circulation       Date:  1971-01       Impact factor: 29.690

3.  Electrocardiographic classification for population comparisons. The Minnesota code.

Authors:  H Blackburn
Journal:  J Electrocardiol       Date:  1969-01       Impact factor: 1.438

4.  Is catch-22 alive and well and living at NHLBI? Reactions to 'digitalis--a new controversy regarding an old drug'.

Authors:  J L Fleiss; J T Bigger; L M Rolnitzky
Journal:  Circulation       Date:  1986-01       Impact factor: 29.690

5.  Problems in clinical trials go far beyond misconduct.

Authors:  R Nowak
Journal:  Science       Date:  1994-06-10       Impact factor: 47.728

6.  Digitalis-associated cardiac mortality after myocardial infarction.

Authors:  A J Moss; H T Davis; D L Conard; J J DeCamilla; C L Odoroff
Journal:  Circulation       Date:  1981-12       Impact factor: 29.690

7.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.

Authors:  T Killip; J T Kimball
Journal:  Am J Cardiol       Date:  1967-10       Impact factor: 2.778

Review 8.  Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure.

Authors:  S Yusuf; R Garg; P Held; R Gorlin
Journal:  Am J Cardiol       Date:  1992-06-04       Impact factor: 2.778

9.  Instantaneous cardiac death in the posthospital period after acute myocardial infarction.

Authors:  M O Sweeney; A J Moss; S Eberly
Journal:  Am J Cardiol       Date:  1992-12-01       Impact factor: 2.778

Review 10.  Digoxin is effective, but is it safe?

Authors:  F I Marcus
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

View more
  4 in total

1.  Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative.

Authors:  Stefano Coiro; Nicolas Girerd; Patrick Rossignol; Johann Bauersachs; Bertram Pitt; Renaud Fay; Giuseppe Ambrosio; Scott D Solomon; Kenneth Dickstein; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2017-04-28       Impact factor: 5.460

2.  Inflammasome inhibition blocks cardiac glycoside cell toxicity.

Authors:  Doris L LaRock; Jenna S Sands; Ethan Ettouati; Marine Richard; Paul J Bushway; Eric D Adler; Victor Nizet; Christopher N LaRock
Journal:  J Biol Chem       Date:  2019-07-12       Impact factor: 5.157

3.  Digoxin use and outcomes after myocardial infarction in patients with atrial fibrillation.

Authors:  Ville Kytö; Antti Saraste; Päivi Rautava; Aleksi Tornio
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-04-22       Impact factor: 3.688

4.  Digoxin intoxication: An old enemy in modern era.

Authors:  Bahadir Kirilmaz; Serkan Saygi; Hasan Gungor; Ugur Onsel Turk; Emin Alioğlu; Serdar Akyuz; Fatih Asgun; Istemihan Tengiz; Ertugrul Ercan
Journal:  J Geriatr Cardiol       Date:  2012-09       Impact factor: 3.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.